G6PD and cancer: A recent study showed that PI3K/AKT activation increased the half-life of the G6PD protein through the inhibition of TRIM21-mediated ubiquitination, and the TRIM21 level had a negative correlation with PI3K/AKT activity in many human cancers [21].